Small Pharma Inc. is a Canada-based neuroscience company that is focused on discovering and developing novel treatments for mental health conditions, with a focus on depression. The Company makes medicines based on known active ingredients and specializes in IP-led development of treatments for mental health conditions through the development of psychedelic and non-psychedelic medicines. The Company’s dimethyltryptamine (DMT) assisted therapy candidates include SPL028 and SPL026. The Company initiated a clinical program into DMT-assisted therapy, including a Phase I/IIa trial on the Company’s lead candidate alongside development of a robust pipeline of proprietary preclinical assets. The Company seeks to initiate Phase I study of SPL028 with psychotherapy among healthy volunteers to assess safety, tolerability, pharmacodynamics and pharmacokinetics of IM and IV administration. SPL026 is a clinical development program with psychotherapy.